PaulAHamlinMD

PubMed

• Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
  Clare Grieve, Ashlee Joseph, Pamela Drullinsky, Andrew D Zelenetz, Paul Hamlin, Anita Kumar> ;Leukemia & Lymphoma. 2024 Feb 1
• Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP.
  Bantilan, K., Smith, A., Maurer, M., Teruya-Feldstein, J., Matasar, M., Moskowitz, A., Straus, D., Noy, A., Palomba, M., Horwitz, S., Hamlin, P., Portlock, C., Cerhan,...> ;Blood Advances. 2024 Jan 25
• 1 citations
  Retrospective characterization of nodal marginal zone lymphoma.
  Robert Stuver, Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip C Caron, Ahmet Dogan, Zachary D Epstein-Peterson, Lorenzo Falchi, Paul A Hamlin,...> ;Blood Advances. 2023 Sep 12
• 3 citations
  TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
  William T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, Alison J Moskowitz, Robert N Stuver, Catherine R Maccaro, Natasha Galasso, Tiffany Chang, Niloufer Khan...> ;Blood Advances. 2023 Sep 12
• Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes.
  Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, Sabela Bobillo Varela, Reiko Nakajima, Laure Michaud, Kanika Gupta, Anastasia Navitski, David Straus, M Lia Palomba, Ali...> ;Haematologica. 2024 Jan 1
• 2 citations
  Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.
  Serena Zheng, Kanika Gupta, Piyush Goyal, Reiko Nakajima, Laure Michaud, Connie Lee Batlevi, Paul A Hamlin, Steven Horwitz, Anita Kumar, Matthew J Matasar, Alison J Mo...> ;Cancers. 2023 Mar 14
• 1 citations
  Development and implementation of an interdisciplinary telemedicine clinic for older patients with cancer-Preliminary data.
  Koshy Alexander, Paul A Hamlin, William P Tew, Kelly Trevino, Amy L Tin, Armin Shahrokni, Elissa Meditz, Manpreet Boparai, Farnia Amirnia, Sung Wu Sun, Beatriz Korc-Gr...> ;Journal of the American Geriatrics Society. 2023 May 1
• 1 citations
  Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
  David Qualls, Brandon S Imber, Michelle Okwali, Paul A Hamlin, Anita Kumar, Oscar B Lahoud, Matthew J Matasar, Ariela Noy, Colette Owens, Andrew D Zelenetz, Victoria S...> ;British Journal of Haematology. 2023 Feb 1
• Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design.
  Anita Kumar, Carla Casulo, Erel Joffe, Craig Moskowitz, John Gerecitano, Alison Moskowitz, Anas Younes, Pamela Drullinsky, Esther Drill, Morgan Choma, Clare Grieve, As...> ;Leukemia & Lymphoma. 2022 Dec 1
• 2 citations
  Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma.
  Paul A Hamlin, Vasile Musteata, Steven I Park, Christine Burnett, Kristina Dabovic, Thomas Strack, Eric T Williams, Banmeet S Anand, Jack P Higgins, Daniel O Persky> ;Cancer Research Communications. 2022 May 1
• 1 citations
  Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
  Fushen Sha, Michelle Okwali, Anna Alperovich, Philip C Caron, Lorenzo Falchi, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Erel Joffe, Niloufer Khan, Anita Kumar,...> ;Blood Cancer Journal. 2022 Feb 10
• 3 citations
  Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug Conjugates
  Julia Canestraro, Malin Hultcrantz, Shanu Modi, Paul A. Hamlin, Alexander N. Shoushtari, Jason A. Konner, William P. Tew, Neil M. Iyengar, Murk Heinemann, David H. Abr...> ;Cornea. 2021 Nov 24
• 2 citations
  Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
  Terry K. Pak, Brianne N. Dixon, Michael J Buege, Phuong H. Dao, Megan H. Leary, Joy C. Jarrett, Tara A. Duggan, Philip Caron, Lorenzo Falchi, Paul A. Hamlin, Audrey Ha...> ;Leukemia & Lymphoma. 2021 Nov 16
• 9 citations
  Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
  Caitlin Stewart, Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank, Paul A. Hamlin, Matthew J. Matasar, John F. Gerecitano, Pamela Dr...> ;Clinical Cancer Research. 2021 Oct 6
• 13 citations
  Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?
  Brandon S. Imber, K. Chau, Jasme Lee, Jisun Lee, Dana L. Casey, J.C. Yang, N. Ari Wijentunga, Annemarie F. Shepherd, Carla Hajj, Shunan Qi, Monica Chelius, Paul A. Ham...> ;Blood Advances. 2021 Oct 26
• 5 citations
  Prephase rituximab/prednisone therapy and aging-related, pro-inflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
  Richard J. Lin, Colette Owens, Esther Drill, Augustine Iannotta, Mayan Oliveros, Dylan L Schick, Ariela Noy, John F. Gerecitano, Pamela Drullinsky, Philip Caron, Anita...> ;Haematologica. 2021 Jul 22
• 15 citations
  Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
  Neha Mehta-Shah, Matthew A. Lunning, Alison J. Moskowitz, Adam M. Boruchov, Jia Ruan, Peggy Lynch, Paul A. Hamlin, John P. Leonard, Matthew J. Matasar, Patricia L. Mys...> ;American Journal of Hematology. 2021 Jul 12
• 69 citations
  Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
  Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Samia Sohail, Alayna Santa...> ;Journal of Clinical Oncology. 2021 Jun 25
• 18 citations
  Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma.
  Parastoo B. Dahi, Jasme Lee, Sean M. Devlin, Josel D. Ruiz, Molly Maloy, Carlos Rondon-Clavo, Erica Petrlik, Roni Tamari, Gunjan L. Shah, Michael Scordo, Matthew J. Ma...> ;Blood Advances. 2021 Jun 22
• 32 citations
  Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
  Sabela Bobillo, Erel Joffe, David Sermer, Patrizia Mondello, Paola Ghione, Philip Caron, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Ma...> ;Blood Cancer Journal. 2021 Jun 16
• 26 citations
  Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
  Anita Kumar, Carla Casulo, Ranjana H. Advani, Elizabeth Budde, Paul M. Barr, Connie Lee Batlevi, Philip Caron, Louis S. Constine, S.V. Dandapani, Esther Drill, Pamela ...> ;Journal of Clinical Oncology. 2021 Apr 28
• 6 citations
  Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.
  Erel Joffe, Yan Leyfman, Esther Drill, Sridevi Rajeeve, Andrew D. Zelenetz, M. Lia Palomba, Craig H. Moskowitz, Carol S. Portlock, Ariela Noy, Steven M. Horwitz, John ...> ;Blood Advances. 2021 Jan 26
• 30 citations
  Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era
  Sabela Bobillo, Erel Joffe, Jessica A. Lavery, David Sermer, Paola Ghione, Ariela Noy, Philip Caron, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, M...> ;Blood. 2021 Jan 7
• 8 citations
  Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by A...
  Anita Kumar, Kurt S. Bantilan, Allison P. Jacob, A. Park, S.F. Schoninger, Craig S. Sauter, Gary A. Ulaner, Carla Casulo, Malek Faham, K.A. Kong, Ravinder K. Grewal, J...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jan 1
• 58 citations
  Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.
  David Sermer, Connie L Batlevi, M. Lia Palomba, Gunjan L. Shah, Richard J. Lin, Miguel-Angel Perales, Michael Scordo, Parastoo B. Dahi, Martina Pennisi, Aishat Afuye, ...> ;Blood Advances. 2020 Oct 13
• Join now to see all

Abstracts/Posters

• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Aging and Hematologic Disorders: Exploring the Evidence 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018